Shareholders approve J.B. Pharma merger with Torrent Pharma
Proposed amalgamation now awaits NCLT approval; shareholders to receive 51 Torrent Pharma shares for every 100 JB Pharma shares held
Proposed amalgamation now awaits NCLT approval; shareholders to receive 51 Torrent Pharma shares for every 100 JB Pharma shares held
Amgen will be prohibited from leveraging its drug portfolio to disadvantage rivals and will be required to seek prior approval before acquiring related products
Subscribe To Our Newsletter & Stay Updated